Investor Ideas Adds Biotech Stocks to Directories: $CZO.V; $CFRX, $HTBX, $KMPH; $IPIX, $HGEN
Other Biotech Additions: $NXTMH.OL, $NANO.OL; $CANTA.ST, $IBT-B.ST; $170900.KS; $FTT.AX, $IMU.AX; $4593.T; $ALHYG.PA; $MXCT.L, $MPH.L
Mining, Energy, Water and Cannabis Stocks also Updated
Point Roberts, WA and Delta, BC - August 25, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week's additions to its global stock directories in biotech, mining, energy, water and cannabis.
Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector. Listings for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.
Biotech companies added include those involved in life sciences, pharmaceuticals, stem cells and medical devices which are addressing a variety of diseases and medical needs including cancer, infection, viral influenza, orthopedics, wound care, premature infant diseases and central nervous system disorders, as well as other rare and/or genetic conditions and diseases.
The stocks are traded across North American and European markets as well as Australia's ASX.
The newest mining company is involved in lithium exploration and development and recently announced an LOI to purchase the cryptocurrency site kaboomcoin.com, entering it into the bitcoin sector of our tech stocks.
The newest energy companies are an oil and gas E&P company working in the Rocky Mountain region and the owner/operator of two oilfields in New Mexico respectively.
Finally, the latest addition in water, PHI Group, Inc. (OTCQB:PHIL) is also a crossover into the agriculture sector, as well as the environment stocks list and the newest cannabis company, CannTrust Holdings Inc. (CSE:TRST) is a federally regulated licensed producer that brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry and currently operates a 50,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario and is upgrading a 430,000 square foot cultivation facility in the Niagara region.
New Biotech Companies Added to Investorideas directory:
Ceapro Inc. (TSX: CZO.V) is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for healthcare and cosmetic industries utilizing the Company's proprietary technology and natural, renewable resources.
Nexstim Plc (Nasdaq OMX: NXTMH) is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain. Nexstim recently filed a 510(k) submission with FDA for NBT® system for the treatment of Major Depressive Disorder (MDD). Nexstim looks forward to introducing the NBT® system for this important indication in early 2018. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.
Cantargia AB (Stockholm: CANTA.ST) is a biotech company that is developing antibody-based treatments for life threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein "IL1RAP", in leukemia stem cells, later research has also identified IL1RAP in a large number of other forms of cancer. The lead compound, CAN04 directed against IL1RAP, will be investigated in the CANFOUR phase I/IIa clinical trial in with primary focus on non-small lung cancer and pancreatic cancer. CAN04 has a dual mechanism of action, it blocks IL1RAP function and stimulates the immune system to eradicate tumor cells. Cantargia's second project is in discovery phase with the goal to develop an IL1RAP binding antibody optimized for therapy of autoimmunity and inflammatory diseases.
ContraFect Corporation (NasdaqCM:CFRX) is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). In addition to CF-301, the company's preclinical programs include potential novel lysins for the treatment of drug-resistant gram-negative pathogens as well as a monoclonal antibody program targeted for the treatment of viral influenza.
Dong-A ST (Korea:170900.KS) develops, manufactures, and markets pharmaceutical products and medical devices worldwide. The company offers various ethical drugs, including Stillen for the treatment of gastritis; Zydena for erectile dysfunction treatment; and Motilitone for use in functional dyspepsia treatment. It also provides incrementally modified drugs, biological products, licensed-in original drugs, and generic drugs; medical devices; microfixation implants for use in artificial joints and plastic surgery to orthopedics and plastic surgeries; medical devices for cardiothoracic surgery and internal medicine of the heart; surgical devices, apparatuses, supplies, and ports enabling the continuous injection of anti-cancer drugs, and catheters; and artificial cardiac circuits for use in open-heart surgery. In addition, the company offers rapid diagnostic test kits, Dong-A Selex On test kits, and blood collection bags; and exports various biological products, finished products, active pharmaceutical ingredients, intermediates, OTC products, non-prescription medicines, health functional foods, and non-pharmaceutical products.
Healios (Tokyo:4593.T) will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of iPSC regenerative medicine products (Stem Cell) as part of the rapid progress of regenerative medicine taking place in the biotechnological revolution.
Hybrigenics SA (EURONEXT: ALHYG.PA) focuses its research and development programs on innovative targets and therapeutics against cancer. Hybrigenics Pharma's research program explores the role of desubiquitination enzymes (DUBs) in the recycling of onco-proteins and the potential benefit of DUB inhibitors as a new class of anti-cancer agents.
Infant Bacterial Therapeutics (Sweden:IBT-B.ST) is a pharmaceutical company based in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
Imugene, Limited (ASX: IMU.AX) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.
Innovation Pharmaceuticals Inc. (OTC:IPIX) formerly Cellceutix Corporation, is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. The Company believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. The Company's Psoriasis drug candidate Prurisol completed a Phase 2 trial and a Phase 2b study is ongoing. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. The Company's anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and the Company has commenced a Phase 2 study in Ovarian Cancer. In the laboratory, Kevetrin has been shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Brilacidin, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative Oral Mucositis (OM) by more than 94% compared to placebo. The Company is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of OM in patients with Head and Neck Cancer; interim results have shown a marked reduction in the incidence of severe OM (WHO Grade ≥ 3). The Company's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). Topline results are now available for the Phase 2, open label Proof-of-Concept trial, treating patients with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). The Company has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.
Nordic Nanovector ASA (Nasdaq OMX: NANO) is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
MaxCyte, Inc.(LSE MXCT.L) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.
Mereo BioPharma Group plc (LSE:MPH.L) is an innovative biopharma company established to address the development and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo focuses on developing and optimising the value of novel medicines acquired from large pharma and biotech designed to address significant unmet medical needs in rare and specialty disease areas.
Heat Biologics (NasdaqCM:HTBX) is an immuno-oncology company developing therapies designed to activate a patient's immune system against cancer. Our ImPACT® and ComPACT™ technologies are designed to turn "cold" tumors "hot" by increasing the ability of tumor infiltrating lymphocytes (TILs) to attack cancer cells. Our PTX-25 antibody, under development by Heat's subsidiary Pelican Therapeutics, is designed to activate memory CD8+ cytotoxic T cells to eliminate tumor cells in patients. These technologies, in combination with other therapies such as checkpoint inhibitors, are intended to address two distinct, but synergistic mechanisms-of-action: robust activation and proliferation of CD8+ T cells, or "killer" T cells, and T cell co-stimulation, to further enhance a patient's immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), to treat patients with non-small, cell lung cancer (NSCLC).
Humanigen, Inc (OTC:HGEN) (formerly KaloBios Pharmaceuticals, Inc.) is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).
KemPharm, Inc. (NasdaqGM: KMPH) is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes its LATTM platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharm's co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company's immediate release abuse deterrent hydrocodone product candidate, KP201.
New Mining Companies:
US Lithium Corp. (OTC: LITH) is an exploration and development company focused in North America on lithium and related resources for the rapidly growing energy storage industry. The Company looks to capitalize on opportunities within the lithium sector including providing lithium to the ever expanding next generation battery market. Lithium demand is projected to triple by the year 2025 according to a recent report by Goldman Sachs and for many analysts is considered the new gasoline of the future. As the demand for lithium expands, U.S. Lithium Corp intends to be an integral part of this next booming industry. Our current focus is in the Basin and Range province of Nevada where the only producing lithium brine mine in North America, Albemarle's Silver Peak Project, is located. Elon, our first project, is located in Clayton Valley and is in close proximity to Silver Peak and several other active explorers and developers. BITCOIN: August 2017: US Lithium Corp. (OTC QB: LITH), announces it has entered into a Letter Of Intent to purchase blockchain based technology assets from Czech Republic software developer Bank Call s.r.o. Under the terms of the agreement LITH will acquire the website kaboomcoin.com, various registered European trademarks and all of the IP associated with kaboomcoin's cryptocurrency wallet.
New Energy Companies:
Foothills Exploration, Inc. (OTCQB:FTXP) based in Denver, Colorado, is a growth stage oil and gas exploration and production (E&P) company with a focus in the acquisition and development of undervalued and underdeveloped properties. The Company's assets are located across well-established plays in the Rocky Mountain region.
Hunter Oil Corp. (OTCQX: HOILF) owns and operates two large, historic oil fields in the Permian Basin of Eastern New Mexico - the Milnesand and Chaveroo fields, which together comprise in excess of 23,000 gross acres, substantially held by production. Historical production of these two fields is approximately 40 million barrels. Hunter has engineered a horizontal redevelopment of the San Andres productive zones. The Company plans to unlock the value in these resource-rich fields by leveraging existing infrastructure, lowering operating costs and increasing efficiencies of its operations.
New Water Companies:
PHI Group, Inc. (OTCQB:PHIL) primarily focuses on acquisitions and invests in select industries and special situations that may substantially enhance shareholder value. It also provides merger and acquisition advisory services through a wholly owned subsidiary, PHI Capital Holdings, Inc. WATER: PHI EZ Water Tech, Inc. is a Wyoming corporation set up by PHI Group to manage, manufacture and market a portfolio of innovative water treatment systems developed by Dr. Martin Nguyen for agriculture and human use.
New Cannabis Companies:
CannTrust Holdings Inc. (CSE:TRST) since its inception in 2014, has led the Canadian market in producing pharmaceutically standardized product. As a federally regulated licensed producer, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates a 50,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario and is upgrading a 430,000 square foot cultivation facility in the Niagara region. CannTrust™ is committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive, global pharma partner, Apotex Inc., are diligently innovating and developing products that will make it easier for patients to use medical cannabis. We support ongoing patient education about medical cannabis and have launched a compassionate use program to support patients with financial needs.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Ideas
Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.
The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more - use our stock directories and access them online 24/7 with login as a member to find your next big idea!
Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp
Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.